Mealey's (August 17, 2020, 1:57 PM EDT) -- WILMINGTON, Del. — A federal judge in Delaware on Aug. 13 ruled that a developer of artificial intelligence (AI) products for the pharmaceutical industry has failed to sufficiently state its claim for trade secret misappropriation under the Defend Trade Secrets Act (DTSA) with the requisite particularity against drug maker AstraZeneca Pharmaceuticals LP, stemming from the defendant's alleged misappropriation of proprietary information it obtained during discussions regarding AstraZeneca's interest in becoming a customer of the developer (Lithero LLC v. AstraZeneca Pharmaceuticals LP, No. 19-2320, D. Del., 2020 U.S. Dist. LEXIS 145592)....